Pralsetinib
Brand names: Gavreto · Active ingredient: Pralsetinib
In short: GAVRETO is indicated for the treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test. GAVRETO is indicated for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion
What is Pralsetinib used for?
GAVRETO is indicated for the treatment of adult patients with metastatic
RET fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test.
GAVRETO is indicated for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate).
This indication is approved under accelerated approval based on overall response rate and duration of response . Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).
âš Boxed warning (FDA's strongest warning)
GAVRETO may increase the risk for serious infections, including bacterial, fungal, viral and opportunistic infections, which can lead to hospitalization or death. Withhold, reduce the dose or permanently discontinue GAVRETO based on severity .
Pralsetinib dosage
Select patients for treatment with GAVRETO based on the presence of a RET gene fusion (NSCLC or thyroid cancer) .
Information on FDA-approved tests for RET gene fusion (NSCLC) is available at http://www.fda.gov/CompanionDiagnostics.
An FDA-approved test for the detection of RET gene fusion (thyroid cancer) is not currently available.
The recommended dosage of GAVRETO is 400 mg orally once daily on an empty stomach (no food intake for at least 2 hours before and at least 1 hour after taking GAVRETO
)
. Continue treatment until disease progression or until unacceptable toxicity.
If a dose of GAVRETO is missed, it can be taken as soon as possible on the same day. Resume the regular daily dose schedule for GAVRETO the next day.
Do not take an additional dose if vomiting occurs after GAVRETO but continue with the next dose as scheduled.
The recommended dose reductions and dosage modifications for adverse reactions are provided in Table 1 and Table 2.
Dose Reduction | Recommended Dosage
First | 300 mg once daily
Second | 200 mg once daily
Third | 100 mg once daily
Permanently discontinue GAVRETO in patients who are unable to tolerate 100 mg taken orally once daily.
The recommended dosage modifications for adverse reactions are provided in Table 2.
Adverse Reactions | SeverityAdverse reactions graded by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03 | Dosage Modification
Serious Infections, Including Opportunistic Infections
| Grade 2 or 3 | Withhold GAVRETO until resolution.Resume at a reduced dose (Table 1).
Grade 4 | Permanently discontinue GAVRETO.
ILD/Pneumonitis
| Grade 1 or 2 | Withhold GAVRETO until resolution. Resume by reducing the dose as shown in Table 1.Permanently discontinue GAVRETO for recurrent ILD/pneumonitis.
Grade 4 | Permanently discontinue GAVRETO.
Hypertension
| Grade 3 | Withhold GAVRETO for Grade 3 hypertension that persists despite optimal antihypertensive therapy. Resume at a reduced dose when hypertension is controlled.
Grade 4 | Discontinue GAVRETO.
Hepatotoxicity
| Grade 3 or 4 | Withhold GAVRETO and monitor AST/ALT once weekly until resolution to Grade 1 or baseline.Resume at reduced dose (Table 1).For recurrent events at Grade 3 or higher, discontinue GAVRETO.
Hemorrhagic Events
| Grade 3 or 4 | Withhold GAVRETO until recovery to baseline or Grade 0 or 1.Discontinue GAVRETO for severe or life-threatening hemorrhagic events.
Other Adverse Reactions
| Grade 3 or 4 | Withhold GAVRETO until improvement to ≤ Grade 2. Resume at reduced dose (Table 1).Permanently discontinue for recurrent Grade 4 adverse reactions. …
How to take Pralsetinib — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Medication Guide).
Serious Infections, Including Opportunistic Infections
Advise patients that GAVRETO may increase the risk of serious infections and to contact their healthcare provider if they experience symptoms of infections .
ILD/Pneumonitis
Advise patients to contact their healthcare provider if they experience new or worsening respiratory symptoms .
Hypertension
Advise patients that they will require regular blood pressure monitoring and to contact their healthcare provider if they experience symptoms of increased blood pressure or elevated readings .
Hepatotoxicity
Advise patients that hepatotoxicity can occur and to immediately contact their healthcare provider for signs or symptoms of hepatotoxicity .
Hemorrhagic Events
Advise patients that GAVRETO may increase the risk for bleeding and to contact their healthcare provider if they experience any signs or symptoms of bleeding .
Tumor Lysis Syndrome
Advise patients to contact their healthcare provider promptly to report any signs and symptoms of TLS .
Risk of Impaired Wound Healing
Advise patients that GAVRETO may impair wound healing. …
Warnings & precautions
Do not take this medicine if: None.
GAVRETO may increase the risk for serious infections, including fatal and opportunistic infections. In the AcceleRET-Lung trial , infections occurred in 72% of patients who received GAVRETO, including 18% with Grade 3, 3.7% with Grade 4, and 7% with fatal outcomes. Among the patients who received chemotherapy/immunotherapy, infections occurred in 52%, including 10% with Grade 3. Infections in the GAVRETO arm included pneumonia, urinary tract infection, opportunistic infections (such as pneumocystis jirovecii pneumonia, and fungal infections) and others. Monitor patients for signs and symptoms of infection and treat appropriately. Withhold, reduce the dose, or permanently discontinue GAVRETO based on severity .
Severe, life-threatening, and fatal interstitial lung disease (ILD) / pneumonitis can occur in patients treated with GAVRETO. Pneumonitis occurred in 12% of patients who received GAVRETO, including 3.3% with Grade 3-4, and 0.2% with fatal reactions.
Monitor for pulmonary symptoms indicative of ILD/pneumonitis. Withhold GAVRETO and promptly investigate for ILD in any patient who presents with acute or worsening of respiratory symptoms which may be indicative of ILD (e.g., dyspnea, cough, and fever). Withhold, reduce dose or permanently discontinue GAVRETO based on severity of confirmed ILD .
Hypertension occurred in 35% of patients, including Grade 3 hypertension in 18% of patients . Overall, 8% had their dose interrupted and 4.8% had their dose reduced for hypertension. Treatment-emergent hypertension was most commonly managed with anti-hypertension medications.
Do not initiate GAVRETO in patients with uncontrolled hypertension. Optimize blood pressure prior to initiating GAVRETO. Monitor blood pressure after 1 week, at least monthly thereafter and as clinically indicated. …
Pralsetinib side effects
The following clinically significant adverse reactions are described elsewhere in the labeling:
Serious Infections, Including Opportunistic Infections
Interstitial Lung Disease/Pneumonitis
Hypertension
Hepatotoxicity
Hemorrhagic Events
Tumor Lysis Syndrome
Risk of Impaired Wound Healing
Embryo-Fetal Toxicity
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The pooled safety population in the WARNINGS AND PRECAUTIONS reflect exposure to GAVRETO as a single agent at 400 mg orally once daily in 540 patients in ARROW . Among 540 patients who received GAVRETO, 71% were exposed for 6 months or longer and 57% were exposed for greater than one year. The most common adverse reactions (≥ 25%) were musculoskeletal pain, constipation, hypertension, diarrhea, fatigue, edema, pyrexia, and cough. The most common Grade 3-4 laboratory abnormalities (≥ 2%) were decreased lymphocytes, decreased neutrophils, decreased hemoglobin, decreased phosphate, decreased leukocytes, decreased sodium, increased aspartate aminotransferase (AST), increased alanine aminotransferase (ALT), decreased calcium (corrected), decreased platelets, increased alkaline phosphatase, increased potassium, decreased potassium and increased bilirubin. …
Drug interactions
Strong or Moderate CYP3A and/or P-gp Inhibitors
Concomitant use with a strong or moderate CYP3A inhibitor and/or a P-gp inhibitor increases pralsetinib exposure [Clinical Pharmacology (12.3)], which may increase the risk of adverse reactions related to GAVRETO. Avoid coadministration of GAVRETO with a strong or moderate CYP3A and/or P-gp inhibitor. If coadministration with any of the above inhibitors cannot be avoided, reduce the GAVRETO dose .
Strong or Moderate CYP3A Inducers
Concomitant use with a strong CYP3A inducer decreases pralsetinib exposure , which may decrease efficacy of GAVRETO. Avoid concomitant use of GAVRETO with strong or moderate CYP3A inducers. If coadministration of GAVRETO with strong or moderate CYP3A inducers cannot be avoided, increase the GAVRETO dose
About this medicine
Pralsetinib is an oral receptor tyrosine kinase inhibitor. The chemical name for pralsetinib is (
cis)-
N-((
S)-1-(6-(4-fluoro-1
H-pyrazol-1-yl)pyridin-3-yl)ethyl)-1-methoxy-4-(4-methyl-6-(5-methyl-1
H-pyrazol-3-ylamino)pyrimidin-2-yl)cyclohexanecarboxamide. The molecular formula for pralsetinib is C
27H
32FN
9O
2, and the molecular weight is 533.61 g/mol. Pralsetinib has the following structure:
The solubility of pralsetinib in aqueous media decreases over the range pH 1.99 to pH 7.64 from 0.880 mg/mL to < 0.001 mg/mL, indicating a decrease in solubility with increasing pH.
GAVRETO (pralsetinib) is supplied for oral use as immediate release hydroxypropyl methylcellulose (HPMC) hard capsules containing 100 mg pralsetinib. The capsules also contain inactive ingredients:
citric acid, hydroxypropyl methylcellulose (HPMC), magnesium stearate, microcrystalline cellulose (MCC), pregelatinized starch and sodium bicarbonate. The capsule shell consists of FD&C Blue #1 (Brilliant Blue FCF), hypromellose and titanium dioxide. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 16edd46e-28b8-f06d-e063-6394a90ae31b. Read the full official label on DailyMed.
Related medicines
Levothyroxine Ergocalciferol Estradiol Ethinyl Estradiol and Norethindrone Alendronate Testosterone Thyroid Norethindrone